Amygdala Neurosciences Inc. has selected ANS-858 as its lead clinical candidate for substance use disorders, that includes ...
alcohol dehydrogenase 1B (ADH1B) and aldehyde dehydrogenase 2 (ALDH2), with behavioral alterations in alcohol consumption could lower excessive alcohol intake. Study: Effectiveness of genetic ...